Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Elastic behavior of model membranes with antimicrobial peptides depends on lipid specificity and d-enantiomers.

Kumagai A, Dupuy FG, Arsov Z, Elhady Y, Moody D, Ernst RK, Deslouches B, Montelaro RC, Peter Di Y, Tristram-Nagle S.

Soft Matter. 2019 Feb 20;15(8):1860-1868. doi: 10.1039/c8sm02180e.

PMID:
30702120
2.

Prevention of ESKAPE pathogen biofilm formation by antimicrobial peptides WLBU2 and LL37.

Lin Q, Deslouches B, Montelaro RC, Di YP.

Int J Antimicrob Agents. 2018 Nov;52(5):667-672. doi: 10.1016/j.ijantimicag.2018.04.019. Epub 2018 May 10.

PMID:
29753132
3.

Elimination of Antibiotic Resistant Surgical Implant Biofilms Using an Engineered Cationic Amphipathic Peptide WLBU2.

Mandell JB, Deslouches B, Montelaro RC, Shanks RMQ, Doi Y, Urish KL.

Sci Rep. 2017 Dec 22;7(1):18098. doi: 10.1038/s41598-017-17780-6.

4.

Enhanced efficacy of the engineered antimicrobial peptide WLBU2 via direct airway delivery in a murine model of Pseudomonas aeruginosa pneumonia.

Chen C, Deslouches B, Montelaro RC, Di YP.

Clin Microbiol Infect. 2018 May;24(5):547.e1-547.e8. doi: 10.1016/j.cmi.2017.08.029. Epub 2017 Sep 4.

PMID:
28882728
5.

Clinical potential of engineered cationic antimicrobial peptides against drug resistant biofilms.

Melvin JA, Montelaro RC, Bomberger JM.

Expert Rev Anti Infect Ther. 2016 Nov;14(11):989-991. Epub 2016 Sep 22. No abstract available.

6.

Simultaneous Antibiofilm and Antiviral Activities of an Engineered Antimicrobial Peptide during Virus-Bacterium Coinfection.

Melvin JA, Lashua LP, Kiedrowski MR, Yang G, Deslouches B, Montelaro RC, Bomberger JM.

mSphere. 2016 May 4;1(3). pii: e00083-16. doi: 10.1128/mSphere.00083-16. eCollection 2016 May-Jun.

7.

Engineered cationic antimicrobial peptide (eCAP) prevents Pseudomonas aeruginosa biofilm growth on airway epithelial cells.

Lashua LP, Melvin JA, Deslouches B, Pilewski JM, Montelaro RC, Bomberger JM.

J Antimicrob Chemother. 2016 Aug;71(8):2200-7. doi: 10.1093/jac/dkw143. Epub 2016 May 26.

8.

Selection of a potential diagnostic biomarker for HIV infection from a random library of non-biological synthetic peptoid oligomers.

Gearhart TL, Montelaro RC, Schurdak ME, Pilcher CD, Rinaldo CR, Kodadek T, Park Y, Islam K, Yurko R, Marques ET Jr, Burke DS.

J Immunol Methods. 2016 Aug;435:85-9. doi: 10.1016/j.jim.2016.05.001. Epub 2016 May 12.

9.

Comparative functional properties of engineered cationic antimicrobial peptides consisting exclusively of tryptophan and either lysine or arginine.

Deslouches B, Hasek ML, Craigo JK, Steckbeck JD, Montelaro RC.

J Med Microbiol. 2016 Jun;65(6):554-65. doi: 10.1099/jmm.0.000258. Epub 2016 Apr 5.

10.

Intestinal Interleukin-17 Receptor Signaling Mediates Reciprocal Control of the Gut Microbiota and Autoimmune Inflammation.

Kumar P, Monin L, Castillo P, Elsegeiny W, Horne W, Eddens T, Vikram A, Good M, Schoenborn AA, Bibby K, Montelaro RC, Metzger DW, Gulati AS, Kolls JK.

Immunity. 2016 Mar 15;44(3):659-671. doi: 10.1016/j.immuni.2016.02.007.

11.

Protective efficacy of centralized and polyvalent envelope immunogens in an attenuated equine lentivirus vaccine.

Craigo JK, Ezzelarab C, Cook SJ, Liu C, Horohov D, Issel CJ, Montelaro RC.

PLoS Pathog. 2015 Jan 8;11(1):e1004610. doi: 10.1371/journal.ppat.1004610. eCollection 2015 Jan.

12.

Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens.

Deslouches B, Steckbeck JD, Craigo JK, Doi Y, Burns JL, Montelaro RC.

Antimicrob Agents Chemother. 2015 Feb;59(2):1329-33. doi: 10.1128/AAC.03937-14. Epub 2014 Nov 24.

13.

Epitope shifting of gp90-specific cellular immune responses in EIAV-infected ponies.

Liu C, Cook SJ, Craigo JK, Cook FR, Issel CJ, Montelaro RC, Horohov DW.

Vet Immunol Immunopathol. 2014 Oct 15;161(3-4):161-9. doi: 10.1016/j.vetimm.2014.08.001. Epub 2014 Aug 10.

14.

Modulation of proinflammatory activity by the engineered cationic antimicrobial peptide WLBU-2.

Paranjape SM, Lauer TW, Montelaro RC, Mietzner TA, Vij N.

F1000Res. 2013 Feb 8;2:36. doi: 10.12688/f1000research.2-36.v1. eCollection 2013.

15.

A hydrolase of trehalose dimycolate induces nutrient influx and stress sensitivity to balance intracellular growth of Mycobacterium tuberculosis.

Yang Y, Kulka K, Montelaro RC, Reinhart TA, Sissons J, Aderem A, Ojha AK.

Cell Host Microbe. 2014 Feb 12;15(2):153-63. doi: 10.1016/j.chom.2014.01.008.

16.

Unique functional properties of conserved arginine residues in the lentivirus lytic peptide domains of the C-terminal tail of HIV-1 gp41.

Kuhlmann AS, Steckbeck JD, Sturgeon TJ, Craigo JK, Montelaro RC.

J Biol Chem. 2014 Mar 14;289(11):7630-40. doi: 10.1074/jbc.M113.529339. Epub 2014 Feb 4.

17.

Structural and functional comparisons of retroviral envelope protein C-terminal domains: still much to learn.

Steckbeck JD, Kuhlmann AS, Montelaro RC.

Viruses. 2014 Jan 16;6(1):284-300. doi: 10.3390/v6010284. Review.

18.

Lessons in AIDS vaccine development learned from studies of equine infectious, anemia virus infection and immunity.

Craigo JK, Montelaro RC.

Viruses. 2013 Dec 2;5(12):2963-76. doi: 10.3390/v5122963. Review.

19.

Antimicrobial peptides: new drugs for bad bugs?

Steckbeck JD, Deslouches B, Montelaro RC.

Expert Opin Biol Ther. 2014 Jan;14(1):11-4. doi: 10.1517/14712598.2013.844227. Epub 2013 Nov 11. Review.

20.

Membrane structure correlates to function of LLP2 on the cytoplasmic tail of HIV-1 gp41 protein.

Boscia AL, Akabori K, Benamram Z, Michel JA, Jablin MS, Steckbeck JD, Montelaro RC, Nagle JF, Tristram-Nagle S.

Biophys J. 2013 Aug 6;105(3):657-66. doi: 10.1016/j.bpj.2013.06.042.

21.

Envelope determinants of equine lentiviral vaccine protection.

Craigo JK, Ezzelarab C, Cook SJ, Chong L, Horohov D, Issel CJ, Montelaro RC.

PLoS One. 2013 Jun 13;8(6):e66093. doi: 10.1371/journal.pone.0066093. Print 2013.

22.

Detailed topology mapping reveals substantial exposure of the "cytoplasmic" C-terminal tail (CTT) sequences in HIV-1 Env proteins at the cell surface.

Steckbeck JD, Sun C, Sturgeon TJ, Montelaro RC.

PLoS One. 2013 May 27;8(5):e65220. doi: 10.1371/journal.pone.0065220. Print 2013.

23.

Rational design of engineered cationic antimicrobial peptides consisting exclusively of arginine and tryptophan, and their activity against multidrug-resistant pathogens.

Deslouches B, Steckbeck JD, Craigo JK, Doi Y, Mietzner TA, Montelaro RC.

Antimicrob Agents Chemother. 2013 Jun;57(6):2511-21. doi: 10.1128/AAC.02218-12. Epub 2013 Mar 18.

24.

Challenges and proposed solutions for more accurate serological diagnosis of equine infectious anaemia.

Issel CJ, Scicluna MT, Cook SJ, Cook RF, Caprioli A, Ricci I, Rosone F, Craigo JK, Montelaro RC, Autorino GL.

Vet Rec. 2013 Feb 23;172(8):210. doi: 10.1136/vr-2012-100735. Epub 2012 Nov 16.

25.

C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic.

Steckbeck JD, Kuhlmann AS, Montelaro RC.

J Gen Virol. 2013 Jan;94(Pt 1):1-19. doi: 10.1099/vir.0.046508-0. Epub 2012 Oct 17. Review.

26.

Development of a high throughput, semi-automated, infectious center cell-based ELISA for equine infectious anemia virus.

Craigo JK, Ezzelarab C, Montelaro RC.

J Virol Methods. 2012 Nov;185(2):221-7. doi: 10.1016/j.jviromet.2012.07.007. Epub 2012 Jul 20.

27.

The determination of in vivo envelope-specific cell-mediated immune responses in equine infectious anemia virus-infected ponies.

Liu C, Cook FR, Cook SJ, Craigo JK, Even DL, Issel CJ, Montelaro RC, Horohov DW.

Vet Immunol Immunopathol. 2012 Aug 15;148(3-4):302-10. doi: 10.1016/j.vetimm.2012.06.018. Epub 2012 Jun 23.

28.

Evaluation of cervical mucosa in transmission bottleneck during acute HIV-1 infection using a cervical tissue-based organ culture.

Shen C, Ding M, Ratner D, Montelaro RC, Chen Y, Gupta P.

PLoS One. 2012;7(3):e32539. doi: 10.1371/journal.pone.0032539. Epub 2012 Mar 7.

29.

Budding of retroviruses utilizing divergent L domains requires nucleocapsid.

Bello NF, Dussupt V, Sette P, Rudd V, Nagashima K, Bibollet-Ruche F, Chen C, Montelaro RC, Hahn BH, Bouamr F.

J Virol. 2012 Apr;86(8):4182-93. doi: 10.1128/JVI.07105-11. Epub 2012 Feb 15.

30.

Bioactivity of WLBU2 peptide antibiotic in combination with bioerodible polymer.

McClanahan JR, Peyyala R, Mahajan R, Montelaro RC, Novak KF, Puleo DA.

Int J Antimicrob Agents. 2011 Dec;38(6):530-3. doi: 10.1016/j.ijantimicag.2011.07.011. Epub 2011 Sep 15.

31.

Highly conserved structural properties of the C-terminal tail of HIV-1 gp41 protein despite substantial sequence variation among diverse clades: implications for functions in viral replication.

Steckbeck JD, Craigo JK, Barnes CO, Montelaro RC.

J Biol Chem. 2011 Aug 5;286(31):27156-66. doi: 10.1074/jbc.M111.258855. Epub 2011 Jun 9.

32.

EQUINE INFECTIOUS ANEMIA VIRUS INFECTION AND IMMUNITY: LESSONS FOR AIDS VACCINE DEVELOPMENT.

Craigo JK, Montelaro RC.

Future Virol. 2011 Feb;6(2):139-142. No abstract available.

33.

Topology of the C-terminal tail of HIV-1 gp41: differential exposure of the Kennedy epitope on cell and viral membranes.

Steckbeck JD, Sun C, Sturgeon TJ, Montelaro RC.

PLoS One. 2010 Dec 7;5(12):e15261. doi: 10.1371/journal.pone.0015261.

34.

Covalent immobilization of antimicrobial peptides (AMPs) onto biomaterial surfaces.

Costa F, Carvalho IF, Montelaro RC, Gomes P, Martins MC.

Acta Biomater. 2011 Apr;7(4):1431-40. doi: 10.1016/j.actbio.2010.11.005. Epub 2010 Nov 5. Review.

PMID:
21056701
35.

Divergence, not diversity of an attenuated equine lentivirus vaccine strain correlates with protection from disease.

Craigo JK, Barnes S, Cook SJ, Issel CJ, Montelaro RC.

Vaccine. 2010 Nov 29;28(51):8095-104. doi: 10.1016/j.vaccine.2010.10.003. Epub 2010 Oct 16.

36.

Relationship of Pneumocystis jiroveci humoral immunity to prevention of colonization and chronic obstructive pulmonary disease in a primate model of HIV infection.

Kling HM, Shipley TW, Patil SP, Kristoff J, Bryan M, Montelaro RC, Morris A, Norris KA.

Infect Immun. 2010 Oct;78(10):4320-30. doi: 10.1128/IAI.00507-10. Epub 2010 Jul 26.

37.

Persistent pneumocystis colonization leads to the development of chronic obstructive pulmonary disease in a nonhuman primate model of AIDS.

Shipley TW, Kling HM, Morris A, Patil S, Kristoff J, Guyach SE, Murphy JE, Shao X, Sciurba FC, Rogers RM, Richards T, Thompson P, Montelaro RC, Coxson HO, Hogg JC, Norris KA.

J Infect Dis. 2010 Jul 15;202(2):302-12. doi: 10.1086/653485.

38.

Human immunodeficiency virus type 1 Vpr: oligomerization is an essential feature for its incorporation into virus particles.

Venkatachari NJ, Walker LA, Tastan O, Le T, Dempsey TM, Li Y, Yanamala N, Srinivasan A, Klein-Seetharaman J, Montelaro RC, Ayyavoo V.

Virol J. 2010 Jun 7;7:119. doi: 10.1186/1743-422X-7-119.

39.

Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load.

Diedrich CR, Mattila JT, Klein E, Janssen C, Phuah J, Sturgeon TJ, Montelaro RC, Lin PL, Flynn JL.

PLoS One. 2010 Mar 10;5(3):e9611. doi: 10.1371/journal.pone.0009611. Erratum in: PLoS One. 2015;10(4):e0124221.

40.

EIAV envelope diversity: shaping viral persistence and encumbering vaccine efficacy.

Craigo JK, Montelaro RC.

Curr HIV Res. 2010 Jan;8(1):81-6. Review.

PMID:
20210783
41.

The lack of an inherent membrane targeting signal is responsible for the failure of the matrix (M1) protein of influenza A virus to bud into virus-like particles.

Wang D, Harmon A, Jin J, Francis DH, Christopher-Hennings J, Nelson E, Montelaro RC, Li F.

J Virol. 2010 May;84(9):4673-81. doi: 10.1128/JVI.02306-09. Epub 2010 Feb 24.

42.

Evaluation of WLBU2 peptide and 3-O-octyl-sn-glycerol lipid as active ingredients for a topical microbicide formulation targeting Chlamydia trachomatis.

Skinner MC, Kiselev AO, Isaacs CE, Mietzner TA, Montelaro RC, Lampe MF.

Antimicrob Agents Chemother. 2010 Feb;54(2):627-36. doi: 10.1128/AAC.00635-09. Epub 2009 Dec 14.

43.

An EIAV field isolate reveals much higher levels of subtype variability than currently reported for the equine lentivirus family.

Craigo JK, Barnes S, Zhang B, Cook SJ, Howe L, Issel CJ, Montelaro RC.

Retrovirology. 2009 Oct 20;6:95. doi: 10.1186/1742-4690-6-95.

44.

HIV-1 matrix dependent membrane targeting is regulated by Gag mRNA trafficking.

Jin J, Sturgeon T, Weisz OA, Mothes W, Montelaro RC.

PLoS One. 2009 Aug 7;4(8):e6551. doi: 10.1371/journal.pone.0006551.

45.

Replication of equine infectious anemia virus in engineered mouse NIH 3T3 cells.

Zhang B, Montelaro RC.

J Virol. 2009 Feb;83(4):2034-7. doi: 10.1128/JVI.01883-08. Epub 2008 Dec 10.

46.

Characterization of an equine macrophage cell line: application to studies of EIAV infection.

Fidalgo-Carvalho I, Craigo JK, Barnes S, Costa-Ramos C, Montelaro RC.

Vet Microbiol. 2009 Apr 14;136(1-2):8-19. doi: 10.1016/j.vetmic.2008.10.010. Epub 2008 Nov 1.

47.

An equine infectious anemia virus variant superinfects cells through novel receptor interactions.

Brindley MA, Zhang B, Montelaro RC, Maury W.

J Virol. 2008 Oct;82(19):9425-32. doi: 10.1128/JVI.01142-08. Epub 2008 Jul 30.

48.

Binding of equine infectious anemia virus to the equine lentivirus receptor-1 is mediated by complex discontinuous sequences in the viral envelope gp90 protein.

Sun C, Zhang B, Jin J, Montelaro RC.

J Gen Virol. 2008 Aug;89(Pt 8):2011-9. doi: 10.1099/vir.0.83646-0.

PMID:
18632973
49.

Comparison of the effects of pathogenic simian human immunodeficiency virus strains SHIV-89.6P and SHIV-KU2 in cynomolgus macaques.

Pawar SN, Mattila JT, Sturgeon TJ, Lin PL, Narayan O, Montelaro RC, Flynn JL.

AIDS Res Hum Retroviruses. 2008 Apr;24(4):643-54. doi: 10.1089/aid.2007.0238.

50.

Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition.

Tagmyer TL, Craigo JK, Cook SJ, Even DL, Issel CJ, Montelaro RC.

J Virol. 2008 Apr;82(8):4052-63. doi: 10.1128/JVI.02028-07. Epub 2008 Jan 30.

Supplemental Content

Loading ...
Support Center